D2AMR: Discovery and development of antimicrobials and resistance mechanisms. PIs: José Antonio Aínsa and Santiago Ramón-García
One of the effective ways to deal with infectious diseases is through the administration of antimicrobial therapies, although the emergence of antimicrobial-resistant bacteria is jeopardizing this therapeutic option. The main lines of research of the D2AMR team include the characterization of mechanisms of intrinsic resistance to antimicrobials, discovery and pre-clinical development of bioactive compounds as new antimicrobials, repositioning of drugs with antimicrobial applications based on synergism, nanoparticles as antimicrobial drug carriers and the development of dynamic pharmacological models for the study of antimicrobial activity.
Our research is mainly focused on M. tuberculosis, on non-tuberculous mycobacteria such as M. abscessus, M. kansasii and M. ulcerans, and on Gram-positive or Gram-negative bacteria with multiple resistance to antibiotics such as Staphylococcus aureus, Streptococcus pneumoniae, Helicobacter pylori and KlebsielLa pneumoniae, among others.